{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:21:56Z","timestamp":1790198516827,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T00:00:00Z","timestamp":1484092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T00:00:00Z","timestamp":1484092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1038\/leu.2017.9","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T07:43:01Z","timestamp":1484120581000},"page":"829-836","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML"],"prefix":"10.1038","volume":"31","author":[{"given":"C","family":"Sch\u00fctz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Inselmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Sausslele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C T","family":"Dietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Eigendorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C A","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S K","family":"Metzelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T H","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Dengler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M E","family":"Goebeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Freunek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Hanzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Illmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Finkernagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Xavier Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Pfirrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Burchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,11]]},"reference":[{"key":"BFleu20179_CR1","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2013","unstructured":"Hehlmann R, M\u00fcller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV. J Clin Oncol 2013; 32: 415\u2013423.","journal-title":"J Clin Oncol"},{"key":"BFleu20179_CR2","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqu\u00e9 C et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014; 123: 494\u2013500.","journal-title":"Blood"},{"key":"BFleu20179_CR3","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26: 2197\u20132203.","journal-title":"Leukemia"},{"key":"BFleu20179_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, J\u00f8rgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319\u2013325.","journal-title":"Blood"},{"key":"BFleu20179_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc3317","volume":"12","author":"T O'Hare","year":"2012","unstructured":"O'Hare T, Zabriskie MS, Eiring AM, Deininger MW . Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 2012; 12: 513\u2013526.","journal-title":"Nat Rev Cancer"},{"key":"BFleu20179_CR6","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","volume":"121","author":"S Branford","year":"2013","unstructured":"Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 2013; 121: 3818\u20133824.","journal-title":"Blood"},{"key":"BFleu20179_CR7","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423\u20131432.","journal-title":"N Engl J Med"},{"key":"BFleu20179_CR8","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","volume":"104","author":"J Cortes","year":"2004","unstructured":"Cortes J, O'Brien S, Kantarjian H . Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204\u20132205.","journal-title":"Blood"},{"key":"BFleu20179_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, R\u00e9a D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58\u201360.","journal-title":"Blood"},{"issue":"Suppl 1","key":"BFleu20179_CR10","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.leukres.2003.10.017","volume":"28","author":"MJ Mauro","year":"2004","unstructured":"Mauro MJ, Druker BJ, Maziarz RT . Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leukemia Res 2004; 28 (Suppl 1): S71\u2013S73.","journal-title":"Leukemia Res"},{"key":"BFleu20179_CR11","first-page":"979","volume":"90","author":"S Merante","year":"2005","unstructured":"Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, Lazzarino M . Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 2005; 90: 979\u2013981.","journal-title":"Haematologica"},{"key":"BFleu20179_CR12","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"F-X Mahon","year":"2010","unstructured":"Mahon F-X, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029\u20131035.","journal-title":"Lancet Oncol"},{"key":"BFleu20179_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2013","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2013; 32: 424\u2013430.","journal-title":"J Clin Oncol"},{"key":"BFleu20179_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515\u2013522.","journal-title":"Blood"},{"key":"BFleu20179_CR15","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NCP Cross","year":"2012","unstructured":"Cross NCP, White HE, M\u00fcller MC, Saglio G, Hochhaus A . Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172\u20132175.","journal-title":"Leukemia"},{"key":"BFleu20179_CR16","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/leu.2009.168","volume":"23","author":"MC M\u00fcller","year":"2009","unstructured":"M\u00fcller MC, Cross NCP, Erben P, Schenk T, Hanfstein B, Ernst T et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 1957\u20131963.","journal-title":"Leukemia"},{"key":"BFleu20179_CR17","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/leu.2015.29","volume":"29","author":"NCP Cross","year":"2015","unstructured":"Cross NCP, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 2015; 29: 999\u20131003.","journal-title":"Leukemia"},{"key":"BFleu20179_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bjh.12892","volume":"166","author":"DM Ross","year":"2014","unstructured":"Ross DM, Hughes TP . How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. Br J Haematol 2014; 166: 3\u201311.","journal-title":"Br J Haematol"},{"key":"BFleu20179_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11899-013-0190-1","volume":"9","author":"M Ilander","year":"2014","unstructured":"Ilander M, Hekim C, Mustjoki S . Immunology and immunotherapy of chronic myeloid leukemia. Curr Hematol Malig Rep 2014; 9: 17\u201323.","journal-title":"Curr Hematol Malig Rep"},{"key":"BFleu20179_CR20","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1200\/JCO.2002.20.1.214","volume":"20","author":"FX Mahon","year":"2002","unstructured":"Mahon FX, Delbrel X, Cony-Makhoul P, Fab\u00e8res C, Boiron JM, Barthe C et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 2002; 20: 214\u2013220.","journal-title":"J Clin Oncol"},{"key":"BFleu20179_CR21","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","volume":"98","author":"F Bonifazi","year":"2001","unstructured":"Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001; 98: 3074\u20133081.","journal-title":"Blood"},{"key":"BFleu20179_CR22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood.V95.1.62","volume":"95","author":"A Hochhaus","year":"2000","unstructured":"Hochhaus A, Reiter A, Sau\u00dfele S, Reichert A, Emig M, Kaeda J et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000; 95: 62\u201366.","journal-title":"Blood"},{"key":"BFleu20179_CR23","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1172\/JCI117473","volume":"94","author":"M Talpaz","year":"1994","unstructured":"Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R . Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest 1994; 94: 1383\u20131389.","journal-title":"J Clin Invest"},{"key":"BFleu20179_CR24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/cncr.11223","volume":"97","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97: 1033\u20131041.","journal-title":"Cancer"},{"key":"BFleu20179_CR25","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/leu.2015.45","volume":"29","author":"A Burchert","year":"2015","unstructured":"Burchert A, Sau\u00dfele S, Eigendorff E, M\u00fcller MC, Sohlbach K, Inselmann S et al. Interferon alpha 2 (IFN) maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia (CML). Leukemia 2015; 29: 1331\u20131335.","journal-title":"Leukemia"},{"key":"BFleu20179_CR26","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood.V69.5.1280.1280","volume":"69","author":"M Talpaz","year":"1987","unstructured":"Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J . Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987; 69: 1280\u20131288.","journal-title":"Blood"},{"key":"BFleu20179_CR27","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/leu.2012.313","volume":"27","author":"M Talpaz","year":"2013","unstructured":"Talpaz M, Hehlmann R, Quint\u00e1s-Cardama A, Mercer J, Cortes J . Re-emergence of interferon-\u03b1 in the treatment of chronic myeloid leukemia. Leukemia 2013; 27: 803\u2013812.","journal-title":"Leukemia"},{"key":"BFleu20179_CR28","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nri3806","volume":"15","author":"J Crouse","year":"2015","unstructured":"Crouse J, Kalinke U, Oxenius A . Regulation of antiviral T cell responses by type I interferons. Nat Rev Immunol 2015; 15: 231\u2013242.","journal-title":"Nat Rev Immunol"},{"key":"BFleu20179_CR29","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/79526","volume":"6","author":"JJ Molldrem","year":"2000","unstructured":"Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018\u20131023.","journal-title":"Nat Med"},{"key":"BFleu20179_CR30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1182\/blood-2002-02-0659","volume":"101","author":"A Burchert","year":"2003","unstructured":"Burchert A, W\u00f6lfl S, Schmidt M, Brendel C, Denecke B, Cai D et al. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 2003; 101: 259\u2013264.","journal-title":"Blood"},{"key":"BFleu20179_CR31","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","volume":"28","author":"A Burchert","year":"2010","unstructured":"Burchert A, M\u00fcller MC, Kostrewa P, Erben P, Bostel T, Liebler S et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010; 28: 1429\u20131435.","journal-title":"J Clin Oncol"},{"key":"BFleu20179_CR32","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nri1349","volume":"4","author":"L Chen","year":"2004","unstructured":"Chen L . Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4: 336\u2013347.","journal-title":"Nat Rev Immunol"},{"key":"BFleu20179_CR33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252\u2013264.","journal-title":"Nat Rev Cancer"},{"key":"BFleu20179_CR34","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH . The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236: 219\u2013242.","journal-title":"Immunol Rev"},{"key":"BFleu20179_CR35","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/ni736","volume":"2","author":"C Asselin-Paturel","year":"2001","unstructured":"Asselin-Paturel C, Boonstra A, Dalod M, Durand I, Yessaad N, Dezutter-Dambuyant C et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2001; 2: 1144\u20131150.","journal-title":"Nat Immunol"},{"key":"BFleu20179_CR36","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nri3027","volume":"11","author":"B Reizis","year":"2011","unstructured":"Reizis B, Colonna M, Trinchieri G, Barrat F, Gilliet M . Plasmacytoid dendritic cells: one-trick ponies or workhorses of the immune system? Nat Rev Immunol 2011; 11: 558\u2013565.","journal-title":"Nat Rev Immunol"},{"key":"BFleu20179_CR37","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.immuni.2008.06.017","volume":"29","author":"A Goubier","year":"2008","unstructured":"Goubier A, Dubois B, Gheit H, Joubert G, Villard-Truc F, Asselin-Paturel C et al. Plasmacytoid dendritic cells mediate oral tolerance. Immunity 2008; 29: 464\u2013475.","journal-title":"Immunity"},{"key":"BFleu20179_CR38","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.immuni.2008.09.002","volume":"29","author":"JA Villadangos","year":"2008","unstructured":"Villadangos JA, Young L . Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 2008; 29: 352\u2013361.","journal-title":"Immunity"},{"key":"BFleu20179_CR39","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1084\/jem.20011603","volume":"195","author":"M Gilliet","year":"2002","unstructured":"Gilliet M, Liu Y-J . Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 2002; 195: 695\u2013704.","journal-title":"J Exp Med"},{"key":"BFleu20179_CR40","doi-asserted-by":"crossref","unstructured":"Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. Terry M. Therneau, (Springer. springer.com, 2000). Available at:http:\/\/www.springer.com\/us\/book\/9780387987842 (Accessed 16 April 2016).","DOI":"10.1007\/978-1-4757-3294-8"},{"key":"BFleu20179_CR41","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/jnci\/86.11.829","volume":"86","author":"DG Altman","year":"1994","unstructured":"Altman DG, Lausen B, Sauerbrei W, Schumacher M . Dangers of using \u2018optimal\u2019 cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829\u2013835.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu20179_CR42","unstructured":"Hothorn T, Hornik K, Zeileis A. Unbiades Recursive Partitioning: A Conditional Interfernce Framework. statmath.wu-wien.ac.at. 2006. Available at: http:\/\/statmath.wu-wien.ac.at\/~zeileis\/papers\/Hothorn+Hornik+Zeileis-2006.pdf (Accessed 16 April 2016)."},{"key":"BFleu20179_CR43","unstructured":"Davison AC, Hinkley DV. Bootstrap Methods and Their Application. statwww.epfl.ch. Available at: http:\/\/statwww.epfl.ch\/davison\/BMA\/CUPsample.pdf (Accessed 16 April 2016)."},{"key":"BFleu20179_CR44","unstructured":"Silverman BW. Density estimation for statistics and data analysis. ned.ipac.caltech.edu. Available at: https:\/\/ned.ipac.caltech.edu\/level5\/March02\/Silverman\/paper.pdf (Accessed 16 April 2016)."},{"key":"BFleu20179_CR45","unstructured":"Altman DG, JM B. Diagnostic tests. 1: Sensitivity and specificity. - PubMed - NCBI. Available at: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8019315."},{"key":"BFleu20179_CR46","unstructured":"Diagnostic tests 2: Predictive values. - PubMed - NCBI. Available at: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8038641."},{"key":"BFleu20179_CR47","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1182\/blood-2014-04-569525","volume":"124","author":"F-X Mahon","year":"2014","unstructured":"Mahon F-X, Richter J, Guilhot J, M\u00fcller MC, Dietz C, Kimmoo P et al. Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study. Blood 2014; 124: 151.","journal-title":"Blood"},{"key":"BFleu20179_CR48","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.4049\/jimmunol.173.7.4433","volume":"173","author":"EA Moseman","year":"2004","unstructured":"Moseman EA, Liang X, Dawson AJ, Panoskaltsis-Mortari A, Krieg AM, Liu Y-J et al. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol 2004; 173: 4433\u20134442.","journal-title":"J Immunol"},{"key":"BFleu20179_CR49","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.4049\/jimmunol.1101855","volume":"189","author":"A Sawant","year":"2012","unstructured":"Sawant A, Hensel JA, Chanda D, Harris BA, Siegal GP, Maheshwari A et al. Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells. J Immunol 2012; 189: 4258\u20134265.","journal-title":"J Immunol"},{"key":"BFleu20179_CR50","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1172\/JCI200316398","volume":"111","author":"JJ Molldrem","year":"2003","unstructured":"Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 2003; 111: 639\u2013647.","journal-title":"J Clin Invest"},{"key":"BFleu20179_CR51","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/ni1333","volume":"7","author":"JC Ochando","year":"2006","unstructured":"Ochando JC, Homma C, Yang Y, Hidalgo A, Garin A, Tacke F et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 2006; 7: 652\u2013662.","journal-title":"Nat Immunol"},{"key":"BFleu20179_CR52","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S1074-7613(00)80284-8","volume":"6","author":"VL Perez","year":"1997","unstructured":"Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK . Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997; 6: 411\u2013417.","journal-title":"Immunity"},{"key":"BFleu20179_CR53","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature01621","volume":"423","author":"H Ueda","year":"2003","unstructured":"Ueda H, Howson JMM, Esposito L, Heward J, Snook H, Chamberlain G et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506\u2013511.","journal-title":"Nature"},{"key":"BFleu20179_CR54","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1074-7613(00)80195-8","volume":"12","author":"B Salomon","year":"2000","unstructured":"Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A et al. B7\/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12: 431\u2013440.","journal-title":"Immunity"},{"issue":"5","key":"BFleu20179_CR55","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/leu.2016.360","volume":"31","author":"M Ilander","year":"2016","unstructured":"Ilander M, Olsson-Str\u00f6mberg U, Schlums H, Guilhot J, Br\u00fcck O, L\u00e4hteenm\u00e4ki H et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia 2016; e-pub ahead of print 16 December 2016 doi:10.1038\/leu.2016.360.","journal-title":"Leukemia"},{"key":"BFleu20179_CR56","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fimmu.2013.00417","volume":"4","author":"A Vasaturo","year":"2013","unstructured":"Vasaturo A, Di Blasio S, Peeters DGA, de Koning CCH, de Vries JM, Figdor CG et al. Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and Go. Front Immunol 2013; 4: 417.","journal-title":"Front Immunol"}],"updated-by":[{"DOI":"10.1038\/leu.2017.348","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T00:00:00Z","timestamp":1517270400000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu20179.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu20179","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu20179.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T17:22:55Z","timestamp":1648747375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu20179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,11]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["BFleu20179"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.9","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/leu.2017.348","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,11]]},"assertion":[{"value":"27 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AB reports personal fees from Bristol-Myers Squibb, outside the submitted work. SS, AH, FXM, MM report honoraria, travel support and research support from Novartis, Bristol-Myers Squibb, Ariad and Pfizer, outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}